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The metabolic cost of lowering blood pressure
with hydrochlorothiazide
Angela L Price1†, Ildiko Lingvay1†, Edward W Szczepaniak2, Jaime Wiebel1, Ronald G Victor2
and Lidia S Szczepaniak2*
Abstract
Background: The landmark Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT)
placed a new spotlight on thiazide diuretics as the first-line therapy for hypertension. This is concerning as thiazide-
diuretics may contribute to comorbidities associated with the current epidemic of obesity. Previous randomized
clinical trials have linked thiazide diuretic treatment to insulin resistance, metabolic syndrome, and increased
incidence of type 2 diabetes.
Methods: This proof of concept, longitudinal, randomized, double–blind study evaluated the effects of the
angiotensin II receptor blocker Valsartan and the specific thiazide diuretic Hydrochlorothiazide (HCTZ) on hepatic
triglyceride level (primary outcome), as well as triglyceride levels within other organs including the heart, skeletal
muscle, and pancreas. Additionally, we evaluated whether myocardial function, insulin sensitivity, and insulin
secretion were affected by these treatments.
Results: Hepatic TG levels increased by 57% post HCTZ treatment: ΔhTG HCTZ = 4.12% and remained unchanged
post Valsartan treatment: ΔhTG V = 0.06%. The elevation of hepatic TG levels after HCTZ treatment was additionally
accompanied by a reduction in insulin sensitivity: ΔSI HCTZ = −1.14. Treatment with Valsartan resulted in improved
insulin sensitivity: ΔSI V = 1.24. Treatment-induced changes in hepatic TG levels and insulin sensitivity were
statistically significant between groups (phTG = 0.0098 and pSI = 0.0345 respectively). Disposition index, DI, remained
unchanged after HCTZ treatment: ΔDI HCTZ = −141 but it was increased by a factor of 2 after treatment with
Valsartan: ΔDI V =1018). However, the change between groups was not statistically significant. Both therapies did
not modify abdominal visceral and subcutaneous fat mass as well as myocardial structure and function.
Additionally, myocardial, pancreatic, and skeletal muscle triglyceride deposits remained unchanged in both
therapeutic arms.
Conclusions: Our findings are two-fold and relate to hepatic steatosis and insulin sensitivity. HCTZ treatment
worsened hepatic steatosis measured as hepatic triglyceride content and reduced insulin sensitivity. Valsartan
treatment did not affect hepatic triglyceride levels and improved insulin sensitivity. The results of this study
reinforce the message that in patients at risk for type 2 diabetes it is particularly important to choose an
antihypertensive regimen that lowers blood pressure without exacerbating patient’s metabolic profile.
Keywords: Type 2 diabetes, Valsartan, Hydrochlorothiazide, Proton magnetic resonance spectroscopy, Insulin
sensitivity, Insulin secretion
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The incidence of obesity and obesity-related complica-
tions such as hypertension and type 2 diabetes are rising
steadily despite the increased public and scientific
awareness of this multifactorial problem. Although spe-
cific efforts to turn the obesity tide concentrate on the
development of new treatment strategies, it is important
to revisit old therapies and review their side effect pro-
files as some treatments may silently augment the meta-
bolic syndrome.
The landmark Antihypertensive and Lipid-Lowering
treatment to prevent Heart Attack Trial (ALLHAT) placed
a new spotlight on thiazide diuretics as the first-line ther-
apy for hypertension [1].This is concerning as thiazide-
diuretics may contribute to comorbidities associated with
the current epidemic of obesity. Previous randomized clin-
ical trials have linked treatment with thiazide diuretic to
insulin resistance, metabolic syndrome, and increased in-
cidence of type 2 diabetes [2,3].
On the contrary, evidence accumulates that therapies
which interfere with the adverse metabolic effects of
angiotensin II, such as angiotensin II receptor blocking
(ARB) or/and angiotensin converting enzyme (ACE I)
therapies, cause no metabolic harm as confirmed by the
DREAM [4] and NAVIGATOR [5-7] studies. The favor-
able metabolic action of ARB and ACE-I agents could
originate from improvement of insulin sensitivity [8] or
could be facilitated through the recruitment and differ-
entiation of adipocytes [9]. Both mechanisms could lead
to reduction in ectopic deposition of triglyceride in or-
gans such as liver, heart, pancreas and skeletal muscle, a
hypothesis that has not yet been tested.
We present the results of a randomized study compar-
ing the metabolic effects of treatment with hydrochloro-
thiazide (HCTZ) and Valsartan in individuals at high
risk for development of type 2 diabetes. We specifically
evaluated the effect of these treatments on intra-hepatic
triglyceride content as well as insulin sensitivity, beta-
cell function, and ectopic triglyceride deposition in the
heart, pancreas, and skeletal muscle.
Methods
This proof of concept, longitudinal, randomized, double–
blind study evaluated two antihypertensive treatments in
individuals at high risk for diabetes. The study was regis-
tered as clinical trial # NCT00745953. The research proto-
col was approved by Institutional Review Board at UT
Southwestern Medical Center. All participants gave in-
formed written consent prior to experiments.
Our objective was to compare the effects of the angioten-
sin II receptor blocker Valsartan and the thiazide diuretic
Hydrochlorothiazide (HCTZ) on hepatic triglyceride level
(primary outcome), as well as triglyceride levels within other
organs including the heart, skeletal muscle, and pancreas.
Additionally, we evaluated whether myocardial function,
insulin sensitivity, and insulin secretion were affected by
these treatments.
Study subjects
Eighty-two individuals were screened for eligibility to
participate in the study. Qualifying individuals were
young adults (age range 18–55 years)with 3 of the fol-
lowing 5 conditions: fasting glucose > 100 mg/dl; waist
circumference: men > 102 cm, women >88 cm; HDL:
men < 40 mg/dl, women <50 mg/dl; TG > 150 mg/dl; BP
> 130/85 mm Hg. Individuals with a previous diagnosis
of type 2 diabetes, stage 2 hypertension (BP > 160/
110 mm Hg), or those exposed to thiazolidinediones,
statins, diuretics, ARB, ACEI, or any investigational
agents within 6 months prior to the study did not qual-
ify. Claustrophobia and presence of metallic implants in
the body were magnetic resonance imaging (MRI) exclu-
sion criteria. Additionally, women of child bearing age
who were not using reliable contraception or those
breast feeding did not qualify.
Twenty-six individuals who qualified and agreed to
participate were randomized in blocks of 4 to either
therapy (12 to HCTZ and 14 to Valsartan). Eight indi-
viduals (5 in HCTZ and 3 in Valsartan) did not complete
the protocol for various personal reasons. Results from 4
individuals who completed therapy (1 in HCTZ and 3 in
Valsartan) were excluded from analysis due to either sig-
nificant lifestyle changes (N = 1) that resulted in a large
amount of weight loss or because individuals were not
available for the end-of-study evaluation (N = 3). Four-
teen individuals (6 in HCTZ and 8 in Valsartan) com-
pleted all study procedures and were considered in final
analysis (Figure 1).
Experimental protocol
Qualified participants were randomized to once-daily
320 mg Valsartan or 25 mg HCTZ therapy for 8 months,
with both agents started at half dose and increased to
full dose after the first month. Notably, one study sub-
ject did not tolerate full dose Valsartan due to relative
hypotension and was; therefore, continued on half dose
(Valsartan 160 mg) for the entire study duration. All
study measurements and procedures were performed at
baseline, 1–7 days prior to randomization and repeated
at the end of the 8-month treatment period.
Procedures
Oral glucose tolerance test (OGTT)
A standard 75 g oral glucose tolerance test was adminis-
tered only at baseline to evaluate each study subject’s
glycemic status according to American Diabetes Associ-
ation criteria [10], and to screen for the presence of un-
diagnosed diabetes. The test was performed at 8:30 AM
after an overnight fast (10–12 hrs) and within 10 days of
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all other baseline measurements. Blood was sampled at
baseline: time ‘0’ and following the standard glucose
drink at 15, 30, 60, 120, and 180 minutes.
Frequently sampled intravenous glucose tolerance test
(FSIVGTT)
The protocol was initiated at 8:30 AM after an overnight
fast (10–12 hours). Two intravenous (antecubical vein)
polyethylene catheters were inserted, one for infusions of
glucose and regular human insulin and another for blood
sampling. A bolus of 50% dextrose solution (0.3 g/kg body
weight) was injected at time 0 and a bolus of regular hu-
man insulin (0.03 U/kg body weight) was injected at
20 min. Blood samples were collected for determination
of plasma glucose and insulin levels at: -15, -10, -5, -1, 2,
3, 4, 5, 6, 8, 10, 14, 19, 22, 25, 30, 40, 50, 70, 100, 140, and
180 minutes. Data were analyzed using the Millennium
Minimal Model (MINMOD) [11]. We report the Acute
Insulin Response to glucose (AIRg) – a measure of glucose
stimulated insulin secretion, Insulin Sensitivity (SI), and
Disposition Index (DI) – a measure of insulin secretion
adjusted for the prevailing insulin sensitivity which pre-
dicts progression to type 2 diabetes [11].
Proton magnetic resonance spectroscopy (MRS)
To study the role of steatosis in the clinical setting, we
and others have developed non-invasive, in vivo tech-
nique that permits the precise and reproducible quantifi-
cation of intracellular triglyceride in various human
organs, including skeletal muscle [12-15], liver [16,17],
myocardium [16,18-21], and pancreas [22]. This method
offers a technological advantage as it distinguishes the
large compartments of triglyceride in adipose tissue cells
from the triglyceride droplets that are stored within the
cytosol of parenchymal cells. This method is now widely
accepted and has become extremely useful in obesity
and diabetes clinical studies as these evaluations are fast,
safe, and reliable. In this study, we evaluated hepatic,
pancreatic, myocardial and skeletal muscle TG content
using a1.5 Tesla Gyroscan Achieva whole body clinical
system (Philips Medical Systems, Cleveland, USA)
equipped with software for localized spectroscopy as de-
scribed before [16,17].In short, high-resolution morpho-
logical images were collected to serve as a “roadmap” for
selection of a testing volume of 27 cc within the upper
right hepatic lobe, 2 cc within pancreatic tail, 6 cc in
myocardial septum, and 1 cc within the skeletal muscle.
All spectra were collected using PRESS sequence (Point
RESolved Spectroscopy) for spatial localization and the
signal acquisition with the following data acquisition pa-
rameters: Te = 27 ms, Tr = 3 s. All data were collected
without water suppression. Sixteen acquisitions were av-
eraged for liver, pancreas, and skeletal muscle, and 32
for heart. Areas of resonances from protons in water
molecules and in methylenes of fatty acid chains were
evaluated with line-fit procedure using a commercial
software (NUTS-ACORNNMR, Freemont, CA) [14-17].
Cardiac imaging
Dynamic cine images were used to quantify left ventricu-
lar (LV) volume [16,18,19]. Image analysis was performed
by an observer blinded to the subject’s clinical history and
treatment, using a commercially available workstation
(MASS, Philips Medical Systems). Endocardial and epicar-
dial LV borders were traced manually at end diastole and
end systole from short-axis slices, and the papillary mus-
cles were excluded from the LV cavity volume. LV mass
was computed as the product of end-diastolic LV volume
and myocardial density (1.05 g/mL). The fraction of blood
pumped out of the left ventricle with each heart beat, the
ejection fraction (EF), was calculated as the difference be-
tween left ventricular end diastolic volume and left ven-
tricular end systolic volume divided by left ventricular end
diastolic volume. EF was used as an index of global LV
function.
Figure 1 Study consort diagram.
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Abdominal MRI
The amount of subcutaneous and visceral abdominal fat
was determined from a single abdominal axial image at
the level between vertebral bodies L2 and L3 [23]. The
image analysis was performed by a single observer who
was blinded to the volunteer’s treatment, using commer-
cially available software (MASS, Philips Medical Sys-
tems) that maps the subcutaneous and intra-abdominal
adipose tissue compartments.
Laboratory measurements
All blood was processed immediately and was analyzed
within 7 days. Lipid profile, liver function tests, glucose,
and insulin were analyzed in a commercial laboratory,
Quest Diagnostics, Irving, TX. HbA1c was analyzed by
HPLC at UT Southwestern Medical Center.
Clinical measurements
Blood pressure was measured with a Space Labs con-
tinuous home monitor for at least a 24 hr period. The
average of all results obtained during this monitoring
period is reported. Waist circumference was measured
at the level of the umbilicus in neutral respiratory pos-
ition, using the same standard tape for all measurements
during the entire study. Hip circumference was mea-
sured at the widest part of the hips.
Statistics
Responses to therapies, measured as a difference be-
tween baseline and end of the study, were compared be-
tween the groups. The tests for normality (Shapiro-Wilk,
chi-square and Kolmogorov-Smirnov) showed that the
hepatic triglyceride content (hTG) response to HCTZ
and disposition index - DI response to Valsartan were
not normally distributed with 95% of confidence based
on the results of at least one of the listed tests. All other
responses, including SI response to both treatments
were normally distributed with 95% confidence. There-
fore we used two sample t-test for comparison of the
central tendency for SI between the two groups. The F-
test was used to compare the variability of the responses
between the two groups. We used non-parametric
Wilcoxon-Mann–Whitney test to compare hTG and DI
responses. Data were analyzed with Statgraphics Centur-
ion XVI software. Statistical significance was set at
p < 0.05.
Results
The characteristics of study participants and the main
study results are listed in Table 1 and Table 2 respect-
ively. Demographic, clinical, and biochemical character-
istics of both groups were similar at baseline and did not
change following either treatment. However, hepatic TG
levels, a measure of hepatic steatosis, increased by 57%
after HCTZ (baseline average hTG = 7.18% +/− 3.30%,
Table 1 Characteristics of study participants (mean ± standard error)
HCTZ Valsartan
Variable Baseline End Baseline End
N 6 9
Male, % 71 22
Age, years 35 ± 11 37 ± 5
Hip circumference, cm 110 ± 6 115 ± 9 116 ± 10 116 ± 10
Waist circumference, cm 101 ± 12 104 ± 16 107 ± 9 107 ± 11
BMI, kg/m2 30.7 ± 2.4 31.6 ± 2.7 34.7 ± 3.4 34.9 ± 3.9
SBP, mmHg 120 ± 11 119 ± 9 114 ± 8 108 ± 9
DBP, mmHg 72 ± 8 71 ± 5 71 ± 7 67 ± 5
HR, beat/min 74 ± 9 77 ± 8 80 ± 7 81 ± 7
Glucose, mg/dL 95 ± 11 98 ± 11 100 ± 10 94 ± 11
Insulin, /mL 7 ± 6 8 ± 4 7 ± 5 9 ± 7
Cholesterol, mg/dL 209 ± 17 217 ± 34 194 ± 40 192 ± 30
Triglycerides, mg/dL 182 ± 118 186 ± 52 153 ± 106 151 ± 83
HDL, mg/dL 40 ± 8 41 ± 6 47 ± 14 49 ± 20
LDL, mg/dL 142 ± 17 139 ± 32 119 ± 31 113 ± 27
HbA1c, % 5.4 ± 0.1 55 ± 0.3 5.4 ± 0.5 55 ± 0.3
ALT, u/L 31 ± 8 31 ± 12 27 ± 25 22 ± 15
AST, u/L 29 ± 8 26 ± 6 21 ± 11 19 ± 6
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hTG range 0.59% - 21.97%; post HCTZ average hTG =
11.30% +/− 4.56%, hTG range 3.13% - 32.37%; and
ΔhTG HCTZ = 4.12%). Hepatic TG levels were unchanged
after Valsartan therapy (baseline average hTG = 8.21%
+/− 3.90%, hTG range 1.62% - 34.92%; post Valsartan
average hTG = 8.27% +/− 3.38%, hTG range 2.83% -
31.49%, and ΔhTG V = 0.06%). The increased inhepatic
TG levels in the HCTZ group were accompanied by a
reduction in insulin sensitivity (baseline average SI =
3.71 +/− 0.98, SI range 1.17 - 7.78; post HCTZ average
SI = 2.57 +/− 0.20, SI range 1.66-3.04; and ΔSI HCTZ =
−1.14). Treatment with Valsartan resulted in improved
insulin sensitivity (baseline average SI = 2.27 +/− 0.68, SI
range 0.46- 6.67; post Valsartan average SI 3.51 +/− 0.80,
SI range 1.28-7.42; and ΔSI V = 1.24). Treatment-
induced changes in hepatic TG levels and insulin sensi-
tivity were statistically significant between groups (phTG
= 0.0098and pSI = 0.0345 respectively). The individual re-
sults as well as the changes in hTG and SI are shown in
Figures 2 and 3.
DI remained unchanged after HCTZ treatment (base-
line average DI = 1332 +/− 399, DI range 471–3255; post
HCTZ average DI = 1191 +/− 312, DI range 372–2339;
and ΔDI HCTZ = −141) but DI increased by a factor of 2
after treatment with Valsartan (baseline average DI =
1016 +/− 157, DI range 473–1819; post Valsartan aver-
age DI 2034 +/− 556, DI range 737 – 5739; and ΔDI V
=1018) – primarily due to improvement in SI. However,
there change between treatment groups was not signifi-
cant. Abdominal (visceral) and subcutaneous fat mass as
Table 2 Hepatic triglyceride content (hTG), insulin secretion (SI) glucose stimulated insulin response (AIRg) and
disposition index (DI) following the eight months treatment with either hydrochlorothiazide (HCTZ) or Valsartan
(mean ± standard error)
HCTZ Valsartan
Variable Baseline End Baseline End
hTG, f/w, % 7.18 ± 3.30 11.53 ± 4.56 8.29 ± 3.90 8.27 ± 3.38
SI, (x10-5/min pmol/l) 3.72 ± 0.98 2.57 ± 0.02 2.27 ± 0.68 3.51 ± 0.8
AIRg, pmol/l 445 ± 291 466 ± 263 701 ± 608 708 ± 405
DI, (x10-5/min) 1332 ± 399 1191 ± 312 1016 ± 157 2034 ± 566
Of note: DI, SI*AIRg and describes the progression to type 2 diabetes when lowered or improvement of metabolic status when raised [11].
Figure 2 Impact of hydrochlorothiazide (HCTZ) and Valsartan treatments on hepatic triglyceride levels (hTG) and insulin sensitivity (SI).
Results of hTG and SI are color coded relative to patient. Black points represent the averages.
Price et al. Diabetology & Metabolic Syndrome 2013, 5:35 Page 5 of 7
http://www.dmsjournal.com/content/5/1/35
well as myocardial structure and function remained un-
changed in both therapeutic arms. Additionally, we did
not detect significant changes in myocardial, pancreatic,
and skeletal muscle triglyceride deposits with these
interventions.
Discussion
We have demonstrated a differential metabolic effect of
two frequently prescribed antihypertensive agents in in-
dividuals at risk for type 2 diabetes. The findings of our
study relate to hepatic steatosis and insulin sensitivity.
HCTZ treatment worsened hepatic steatosis measured
as hepatic TG content and reduced insulin sensitivity.
Valsartan treatment did not affect hepatic TG levels and
improved insulin sensitivity. The results of this study
reinforce the message that in patients at risk for type 2
diabetes it is particularly important to choose an antihy-
pertensive regimen that lowers blood pressure without
exacerbating patient’s metabolic profile.
Our results parallel the earlier reported findings from
the MEDICA study [24]. MEDICA investigators reported
similar worsening in hepatic triglyceride content and insu-
lin sensitivity following 3 months of treatment with 50 mg
of HCTZ and observed no change of hepatic triglyceride
levels following treatment with another ARB class medica-
tion Candesartan. In light of such tight agreement of
two independent studies, therapy with HCTZ - widely
accepted as first-line agent for treating hypertension -
should be re-evaluated. HCTZ offer affordable and effi-
cient blood pressure lowering but come with the added
cost of worsening metabolic profiles for diabetes. This can
occur even at doses of 25 mg and is sustained over a lon-
ger treatment period (8 months). By the same means, the
ARB agents improve insulin sensitivity and did not cause
fatty liver.
Primum non nocere - our treatment choices should
not only improve the primary condition for which they
are prescribed, but we must ensure that our patients suf-
fer no harm. The ultimate goal of any antihypertensive
therapy is to prevent cardiovascular events. The use of
an antihypertensive agent that worsens hepatic steatosis
and insulin resistance, both of which promote cardiovas-
cular disease, negates the ultimate cardiovascular-
preventive goal of the treatment. Hypertension clusters
with metabolic syndrome, diabetes, and hepatic steatosis,
and requires life-long pharmacologic treatment. When all
aspects are balanced i.e. the blood pressure lowering effect
and the worsening metabolic profile the use of HCTZ as a
first line therapeutic choice should be questioned.
The underlying mechanism of the deleterious meta-
bolic action of HCTZ is still debated although our re-
sults implicate concomitant worsening of fatty liver and
decreased insulin sensitivity. Chronic exposure to angio-
tensin II may render fat cells less efficient in their cap-
acity to adequately store excess triglyceride, resulting in
tissue overflow with ectopic triglyceride and ultimately
hepatic steatosis. Interestingly, blocking the renin-
angiotensin system by Valsartan did not result in fatty
liver. The favorable metabolic action of Valsartan is
probably complex and could originate from improve-
ment of insulin sensitivity [8] or it could be facilitated
through the recruitment and differentiation of adipo-
cytes [25]. In light of the above-mentioned observations
it seems natural to hypothesize that pairing ARB with
HCTZ could block angiotensin II and mitigate the ad-
verse metabolic effects induced by HCTZ. Regrettably,
an attempt to block these unfavorable metabolic effects
of HCTZ by combining it with losartan was not success-
ful [26].
We acknowledge that this study is small and these re-
sults should be replicated, yet the effect size was consid-
erable and very comparable to that found in a similar
independently conducted study [24]. We also note that
small sample size did not allow us to further explore the
mechanisms that contribute to our observations.
Conclusions
We have documented that HCTZ therapy leads to the
development of hepatic steatosis and compromised insu-
lin sensitivity in subjects at high risk for type 2 diabetes.
Figure 3 (a) Changes in hepatic triglyceride content (hTG) after
treatment with Valsartan and HCTZ ( p = 0.0098). (b) Changes in
insulin sensitivity (SI) after treatment with HCTZ and
Valsartan (p = −0.0345).
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Conversely, treatment with Valsartan did not cause ec-
topic fat redistribution, and in fact, leads to improved in-
sulin sensitivity. Further studies are needed to determine
the exact mechanism by which HCTZ exerts its deleteri-
ous effects and whether these changes in metabolic
parameters will translate into an increase in major long-
term adverse cardiovascular events. While the clinical
relevance of thiazide-induced metabolic derangements
remains uncertain at this time, hypertensive individuals
at risk for diabetes and those with known hepatic
steatosis should opt for antihypertensive agents that are
metabolically benign – i.e. ARB or ACE inhibitors –
until this issue is clarified.
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